Shares of Virios Therapeutics, Inc. (NASDAQ:VIRI - Get Free Report) shot up 14.5% on Friday . The company traded as high as $5.09 and last traded at $4.27. 1,997,131 shares traded hands during trading, an increase of 90% from the average session volume of 1,049,645 shares. The stock had previously closed at $3.73.
Virios Therapeutics Price Performance
The stock has a market cap of $105.15 million, a price-to-earnings ratio of -20.22 and a beta of 1.58. The company's fifty day moving average price is $5.36 and its 200-day moving average price is $4.75.
Virios Therapeutics Company Profile
(
Get Free Report)
Virios Therapeutics, Inc, a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia.
Further Reading
Before you consider Virios Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Virios Therapeutics wasn't on the list.
While Virios Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
